4-20-16 $CTIX ~ Cellceutix Corp. Due Diligence Report

New Post Public Reply Private Reply Replies (0) Message Board
TheHound
4-20-16 $CTIX ~ Cellceutix Corp. Due Diligence Report

BULLISH




$CTIX news

http://www.cellceutix.com/category/press-rele...r967e.dpbs


Latest PR's from Cellceutix:


Tues, 19 April 2016 ~ Cellceutix Institutes "Database Soft Lock" on Its Phase 2 Psoriasis Clinical Trial, Top Line Results Anticipated in May; Additional Company Updates

read more: http://cellceutix.com/cellceutix-institutes-d...ny-updates


Thur, 31 Mar 2016 ~ Cellceutix Successfully Completes In Vitro Study in Support of Planned Phase 2 Trial of Kevetrin for Ovarian Cancer

read more: http://www.marketwired.com/press-release/cell...110659.htm


Wed, 30 Mar 2016 ~ Cellceutix Receives Preliminary Approval for Clinical Trial of Brilacidin for Ulcerative Proctitis

read more: http://cellceutix.com/cellceutix-receives-pre...ott2H.dpbs


Thur, 17 Mar 2016 ~ Cellceutix Concludes Last Patient Visit in Phase 2 FDA Trial of Oral Dosed Prurisol in Patients With Mild-to-Moderate Chronic Plaque Psoriasis

read more: http://cellceutix.com/cellceutix-concludes-la...cJyzj.dpbs



Tue, 8 Mar 2016 ~ Cellceutix Corporation Welcomes Dr. Stephen T. Sonis to Its Scientific Advisory Board

read more: http://cellceutix.com/cellceutix-corporation-...Z3WZS.dpbs


Tue, 1 Mar 2016 ~ Cellceutix Completes Dosing in Phase 2 Trial of Prurisol for Chronic Psoriasis, Top-Line Data Anticipated in May

read more: http://cellceutix.com/cellceutix-completes-do...hDdHN.dpbs


Fri, 26 Feb 2016 ~ Cellceutix Submits Special Protocol Assessment Request to FDA for Phase 3 Clinical Trial of Brilacidin for ABSSSI

read more: http://cellceutix.com/cellceutix-submits-spec...v1FSM.dpbs


$CTIX filings - Perhaps the most important section

http://www.sec.gov/cgi-bin/browse-edgar?compa...getcompany


$CTIX charts

basic chart ## source: stockscores.com




$CTIX company information

## source: otcmarkets.com

Link: http://www.otcmarkets.com/stock/CTIX/company-info
Ticker: $CTIX
OTC Market Place: OTC Pink Current
CIK code: 0001355250
Company name: Cellceutix Corp.
Company website: http://www.cellceutix.com
Incorporated In: NV, USA


Additional $CTIX company information:

## source: Opinion summary from various sources.

Business Description: Headquartered in Beverly, Massachusetts, Cellceutix is a publicly traded company under the symbol "CTIX". Cellceutix is a clinical stage biopharmaceutical company developing innovative therapies in multiple diseases. Cellceutix believes it has a world-class portfolio of compounds and is now engaged in advancing its compounds and seeking strategic partnerships. Cellceutix's anti-cancer drug Kevetrin concluded a Phase 1 clinical trial at Harvard Cancer Centers' Dana Farber Cancer Institute and Beth Israel Deaconess Medical Center, and Cellceutix is now preparing its FDA application for a Phase 2 ovarian cancer study. In the laboratory Kevetrin has shown to induce activation of p53, often referred to as the "Guardian Angel Gene" due to its crucial role in controlling cell mutations. Cellceutix is in a Phase 2 clinical trial with its novel compound Brilacidin-OM for the prevention of Oral Mucositis in patients with head and neck cancer. Brilacidin-OM, a defensin mimetic compound, has shown in an animal model to reduce the occurrence of severe ulcerative oral mucositis by more than 94% compared to placebo. Cellceutix's anti-psoriasis drug Prurisol is in a Phase 2 trial. Prurisol is a small molecule that acts through immune modulation and PRINS reduction. Cellceutix's lead antibiotic, Brilacidin, has completed a Phase 2b trial for Acute Bacterial Skin and Skin Structure Infections, or ABSSSI. Top-line data have shown a single dose of Brilacidin to deliver comparable clinical outcomes to the FDA-approved seven-day dosing regimen of daptomycin. Brilacidin has the potential to be a single-dose therapy for certain multi-drug resistant bacteria (Superbugs). Cellceutix has formed research collaborations with world-renowned research institutions in the United States and Europe, including MD Anderson Cancer Center, Beth Israel Deaconess Medical Center, and the University of Bologna. More information is available on the Cellceutix web site at www.cellceutix.com.

To find more information on completed and active Human Clinical Trials, please click the below link.

https://www.clinicaltrials.gov/ct2/results?te...rch=Search


$CTIX Share Structure

## source: otcmarkets.com

Market Value: $132,602,100 a/o Feb 09, 2016
Shares Outstanding: 118,500,536 a/o Oct 31, 2015
Float: Not Available
Authorized Shares: 300,000,000 a/o May 12, 2008
Par Value: 0.0001

Various $CTIX DD links

Cellceutix Corp. website - http://www.cellceutix.com
Company Email - info@cellceutix.com
Management - http://cellceutix.com/team/
Product Pipeline - http://cellceutix.com/pipeline/
Recent News and Press Releases - http://finance.yahoo.com/q/h?s=CTIX+Headlines
SEC Filings - http://www.sec.gov/cgi-bin/browse-edgar?compa...getcompany
Financials - http://www.otcmarkets.com/stock/CTIX/financials
Transfer Agent - http://www.westcoaststocktransfer.com/
Short Interest - http://www.otcmarkets.com/stock/CTIX/short-sales
Key Statistics - http://www.finance.yahoo.com/q/ks?s=CTIX+Key+Statistics
Insider Roster - http://www.finance.yahoo.com/q/ir?s=CTIX+Insider+Roster
Insider transactions - http://www.secform4.com/insider-trading/CTIX.htm
Income Statement - http://finance.yahoo.com/q/is?s=CTIX
Balance Sheet - http://www.finance.yahoo.com/q/bs?s=CTIX
Cash Flow - http://www.finance.yahoo.com/q/cf?s=CTIX+Cash...amp;annual


Cellceutix IP - Patent Filings:

EPO
http://worldwide.espacenet.com/searchResults?...pact=false
WIPO
http://www.wipo.int/patentscope/search/en/det...ing=FP src="/images/icons/icon_sad.gif" class="post_smiley" /> Cellceutix)&maxRec=1
USPTO
http://appft.uspto.gov/netacgi/nph-Parser?Sec...amp;d=PG01

http://patft.uspto.gov/netacgi/nph-Parser?Sec.../8,796,275


********************************************************

**The below section courtesy of Slcimmuno**

1) PIPELINE MILESTONES/CATALYSTS

Oncology

- Completion of K Phase 1 (Solid Tumor) -- article has been submitted to a peer review journal for publication

- Initiation of several other K Phase 2, 2/3 trials -- ovarian, pediatric retinoblastoma, pancreatic, AML... this last one w/ Bologna on hold pending financing; in future trials, K to be evaluated as a monotherapy and as a combo therapy; more frequent dosing likely (eg, 2-3x week); company pursuing outside grant support; addtl Orphan designations possible beyond the two already awarded for ovarian, pediatric retinoblastoma; more expedited pathway designations possible, e.g., Breakthrough Therapy

See:
http://www.fda.gov/downloads/AboutFDA/Centers...447162.pdf

Infectious Disease / Antibiotics

- Start of B-ABSSSI Phase 3 -- Brilacidin represents a new class of ABX, Host Defense Protein (HDP)-Mimics; given as a single dose (in Ph 2 compared favorably w/Daptomycin); two trials, approximately 1400 patients btw them; also a Pediatric Study Plan submitted to FDA for use in children; eventual Fast-Track designation, per QIDP

See:
https://en.wikipedia.org/wiki/Brilacidin

See:
http://www.researchgate.net/profile/Chandradh...8a1ca5.pdf

- Phase 2 B-OM (oral mucositis) -- FDA has granted Fast Track status; great unmet need here; recruitment ongoing, additional enrollment sites being pursued

- ABX platform progress -- advancing work on anti-fungals (Candida species, aspergillus); anti-biofilm (MTA signed for B-prophylactic testing with a Big Rx); gram-neg compounds targeting Pseudomonas, Klebsiella, E. Coli, Acinetobacter. Carbapenem-resistant Enterobacteriaceae (CRE); GI indiciations, givien B's immunomodulatory properties (Ulcerative Proctitis/Colitis, H Supportiva); topical applications for Otic Infections

Dermatology

- Phase 2 Prurisol update -- Trial is complete (plaque psoriasis). Top-line data is expected to be available in the next few weeks.

2) OPERATIONS

- Financing in place (shelf, Aspire)
- 1st Shareholder meeting (Dec 15)
- NASDAQ uplisting
- Class Action Defense (Legal/Sullivan)
- Partners: more a question of when not if as science continues to prove out -- could happen anytime. One case study, see CELG-Nurix deal (p53)

https://blogs.shu.edu/cancer/2015/09/30/ubiqu...d-celgene/

3) CURRENT TRIALS

http://www.clinicaltrials.gov/ct2/results?ter...rch=Search

1. P (Phase 1, Successful Completion): http://www.clinicaltrials.gov/ct2/show/NCT021...amp;rank=1

P (Phase 2, Trial Complete - Awaiting Results): http://www.clinicaltrials.gov/ct2/show/NCT024...amp;rank=2

2. B-OM (Phase 2, Active, Recruiting): http://www.clinicaltrials.gov/ct2/show/NCT023...amp;rank=3

3. K (Phase 1, Successful Completion): http://www.clinicaltrials.gov/ct2/show/NCT016...amp;rank=4

4. B-ABSSSI (Phase 2, Successful Completion): http://www.clinicaltrials.gov/ct2/show/NCT020...amp;rank=5

Abbreviations

K – Kevetrin
B – Brilacidin
P – Prurisol
OM – oral mucositis
ABSSSI – acute bacterial skin and skin structure infections
QIDP – qualified infectious disease product

Company Website:
http://www.cellceutix.com

Innovation Pharmaceuticals Inc (IPIX) Stock Research Links

IPIX Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

U.S. Employers Signal a Deeper Multilingual Skills Gap

Updated Category News Views 125

A language gap rarely makes the loudest noise in an earnings call, yet it can quietly wreck a sales effort, a hiring plan, or a customer relationship. ACTFL's updated 2026 employer study puts some hard edges around that problem: U.S. businesses say multilingual capability is not a nice cultural accessory. It is increasingly part of operating the business. Demand Has Moved...

Continue Reading
Travel Disruptions Reveal the Value of Human Support

Updated Category News Views 119

Air travel’s ugly little secret surfaced again during the recent ground stop: a reservation is easy, but rescuing a trip is labor-intensive, fast-moving work. Internova Travel Group says its people across Travel Leaders Network, Global Travel Collection and ALTOUR moved quickly as cancellations piled up and travelers were left staring at busted itineraries. That is not...

Continue Reading
S&P Global's UBS AI Conference Slot Deserves Attention

Updated Category News Views 109

Thirty Minutes Can Still Matter A half-hour fireside chat is not a quarterly earnings call, and anybody treating it like one is setting themselves up for disappointment. Still, S&P Global CEO Martina Cheung appearing at the UBS Global Technology and AI Conference on December 2 deserves a spot on the calendar for owners of NYSE:SPGI. This is a company sitting in the middle...

Continue Reading
Lennar's 6.73% Slide Puts Disclosure Claims in Focus

Updated Category News Views 93

A homebuilder can survive ugly margins; murky demand signals are another beast entirely. Lennar is staring at a securities class action after a bruising run of disclosures and market reactions, and the central issue is not whether housing got tougher. Everybody with a pulse knew rates were squeezing buyers. The issue is whether NYSE:LEN gave investors a sufficiently clear...

Continue Reading
Cottage Grove Tests Holiday Demand Across Lake Norman

Updated Category News Views 120

Flour and foot traffic make a pretty honest little scoreboard. Cottage Grove Bakery is putting itself in front of Lake Norman shoppers twice on Saturday, November 21, while also taking Thanksgiving orders and laying groundwork for 2027 workplace and school visits. This is not a public-company earnings story, and nobody should pretend a tray of scones is a quarterly...

Continue Reading
Simmons Clarifies Texas Loan Exposure, But Risks Remain

Updated Category News Views 87

A $45 million discrepancy is not a rounding error, and Simmons First National has every reason to swat it down hard. The bank says recent reporting overstated financing tied to a Texas multifamily development at $133 million. Its stated total is roughly $88 million, with about $44 million participated to another financial institution. For shareholders in NASDAQ:SFNC, that...

Continue Reading
Allooloo's 100M Calls Test Capital Markets AI Data

Updated Category News Views 138

Forty-one point nine thousand issuers is a lot of financial clutter to keep straight, and Allooloo says its machines are getting called on to do precisely that at industrial scale. The Vancouver-based company reported on November 20 that its capital-markets data products now receive 100 million AI-agent calls a month—roughly 3.4 million daily, or 39 per second. That is...

Continue Reading
PexarBolt's CES Honor Meets a Real Crowdfunding Test

Updated Category News Views 52

A little touchscreen bolted onto a dock would usually make me roll my eyes. This time, Pexar has at least put enough muscle behind the gimmick to deserve a harder look. The PexarBolt Ultra TBT5 Dock was named a CES Innovation Awards 2027 Honoree in Computer Peripherals & Accessories, following an IFA 2026 Innovation Awards honor only two months after its launch. Awards do...

Continue Reading
Surf City Seasons Put Vacation Rental Timing in Focus

Updated Category News Views 42

Summer’s Calendar Does the Talking School bells, not seagulls, appear to set the pace for Surf City’s rental market. Chris Rackley’s seasonal guide makes a pretty grounded point: the “best” time to visit Surf City, North Carolina, is not some universal magic week on a postcard. It depends on whether a traveler needs peak beach weather, wants elbow room, or...

Continue Reading
Dallas College Recognition Signals Workforce Value

Updated Category News Views 63

Economic mobility rarely arrives with brass bands, but it can show up in a community-college ranking. Dallas College has landed on TIME and Statista's inaugural America’s Best Community Colleges 2027 list, one of 250 schools selected from roughly 1,100 nationwide. For a region that keeps talking about talent pipelines, this is a useful piece of outside validation—not...

Continue Reading

Top 5 Most Recently Viewed Articles

Hyundai Unveils Palisade with John Krasinski for Epic Campaign

Updated Category News Views 223

Hyundai Launches 'Make Everyday Epic' Campaign Hyundai is thrilled to announce its latest marketing strategy highlighted by the Palisade Hybrid SUV, a vehicle designed to enrich everyday experiences. With its stunning aesthetics and performance capabilities, the Palisade emerges as a perfect choice for those seeking a touch of luxury in their daily activities. Epic...

Continue Reading
Olympus Corporation Updates Landscape with New CPT Codes

Updated Category News Views 238

Olympus Corporation Introduces New CPT Codes for ESD Olympus Corporation, a pioneering global medical technology company, has taken a significant step towards enhancing patient care in the realm of gastrointestinal health. Recently, the American Medical Association (AMA) announced the establishment of new Category I CPT codes for the Endoscopic Submucosal Dissection (ESD)...

Continue Reading
Audience Town's Conversion-Focused Tool Transforms Home Building

Updated Category News Views 156

Introducing Audience Town's New Tool for Home Builders Audience Town, a pioneering platform in home building performance analytics, has recently launched the Audience Targeting Add-On. This innovative tool marks a significant milestone for builders, providing them with the ability to retarget their highest-value website visitors effectively, effectively eliminating...

Continue Reading
Investor Class Action Alerts: Navigating Recent Legal Developments

Updated Category News Views 182

Investor Class Action Alerts: An Overview In today's marketplace, investors remain vigilant against various legal risks as class action lawsuits emerge against publicly traded companies. These lawsuits can significantly affect shareholders who are often left navigating complex legal landscapes. A recent reminder from The Law Offices of Frank R. Cruz regarding upcoming...

Continue Reading
Elisity’s Texas Water Pilot Puts IonQ’s Deal in View

Updated Category News Views 261

Water-system security is not a place for chest-thumping Elisity’s role in Texas Project Watershed 250 lands on a problem that is painfully concrete: water and wastewater utilities have to keep pumps, treatment systems and plant operations running while trying to close cybersecurity gaps. That is a tougher job than selling another dashboard to a corporate IT department....

Continue Reading